Axsome Therapeutics (AXSM)

• Market cap: $5.45B
• 1 day: -4.25%
• 5 days: -7.53%
• 1 month: -12.17%
• 3 months: 27.89%
• 6 months: 23.38%
• Year to date: 27.89%
• 1 year: 45.04%
• 5 years: 100.16%
• 10 years: 1,177.69%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Employees: 589

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

61% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 38

49% more call options, than puts

Call options by funds: $181M | Put options by funds: $121M

38% more funds holding in top 10

Funds holding in top 10: 8 [Q3] → 11 (+3) [Q4]

5% more funds holding

Funds holding: 274 [Q3] → 288 (+14) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 90 | Existing positions reduced: 90

1.93% less ownership

Funds ownership: 80.18% [Q3] → 78.26% (-1.93%) [Q4]

9% less capital invested

Capital invested by funds: $3.46B [Q3] → $3.14B (-$312M) [Q4]

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $143 28% upside
• Avg. target: $174 56% upside
• High target: $216 93% upside

13 analyst ratings

• positive: 13 100%
• neutral: 0 0%
• negative: 0 0%

Needham Ami Fadia 29% 1-year accuracy 50 / 171 met price target	37% upside $153	Buy Reiterated	1 Apr 2025
Mizuho Graig Suvannavejh 32% 1-year accuracy 8 / 25 met price target	93% upside $216	Outperform Maintained	27 Mar 2025
HC Wainwright & Co. Raghuram Selvaraju 34% 1-year accuracy 117 / 342 met price target	79% upside $200	Buy Reiterated	6 Mar 2025
Baird Joel Beatty 45% 1-year accuracy 18 / 40 met price target	43% upside $160	Outperform Maintained	3 Mar 2025
Morgan Stanley Vikram Purohit 29% 1-year accuracy 2 / 7 met price target	70% upside $190	Overweight Maintained	27 Feb 2025